🧬 Endocrinology Update: Glipizide Heart Risk, AI Osteoporosis Screening, PCOS Insights and More
Stay on top of the latest breakthroughs in endocrinology with this week’s essential updates! From cardiovascular risks in diabetes treatments to cutting-edge AI screening tools, we bring you concise, evidence-based insights that matter for clinical practice and research.
📌 In This Episode:
❤️ Glipizide linked to the highest five-year cardiovascular event risk in type 2 diabetes
🧮 New nomogram surpasses ATA guidelines for predicting thyroid cancer recurrence
🧒 Pfizer’s somatrogon safety study in pediatric growth hormone deficiency progresses
🧬 Genetic evidence reveals causal links between lipids, immune cells, and PCOS
🩻 AI-powered chest X-ray screening proves cost-effective for osteoporosis detection
💊 Entera Bio’s first oral anabolic osteoporosis therapy advances to Phase 3 trials
📡 Medtronic unveils Abbott CGM integration for MiniMed insulin systems
🧍♂️ One in three diabetes cases remain undiagnosed across Europe
🏭 Mankind Pharma confident in growth despite GLP-1 market expansion
🧪 Sanofi launches early detection study for type 1 diabetes in at-risk youth
These developments highlight how technology, genetics, and targeted drug design are transforming endocrine disease management—from prevention to personalized treatment.
📢 Stay Ahead in Endocrinology Research!
✅ Like, share, and subscribe for weekly updates on endocrinology and related diseases
#Endocrinology #Diabetes #ThyroidCancer #PCOS #Osteoporosis #GrowthHormone #CardiovascularRisk #MedicalNews #ClinicalResearch #AIinHealthcare